IP Library › Granted Patent US 10,967,000
Granted Patent B2
US 10,967,000 · App. 14/413,732 · Granted Apr 6, 2021

Cell-penetrating peptide, conjugate comprising same and composition comprising same

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: Gemvax & Kael Co., Ltd.
A61K31/711A61K31/713A61K47/64A61K48/0041A61K49/0047A61K49/0056A61K49/14C07K7/08A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,967,000
App. No.
14/413,732
Granted
Apr 6, 2021
Kind
B2
Abstract

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Claims (23)

1. A conjugate of a carrier peptide and an active ingredient,

wherein the carrier peptide is an isolated peptide 16 amino acids in length and consists of the amino acid sequence of SEQ ID NO: 1;

wherein the carrier peptide and the active ingredient are connected via a covalent bond, or via a linker;

and the active ingredient is not telomerase or a fragment thereof.

2. The conjugate according to claim 1 , wherein the active ingredient is a protein.

3. The conjugate according to claim 1 , wherein the active ingredient is connected to the C-terminus of the carrier peptide.

4. A composition comprising the conjugate according to claim 1 .

5. The composition according to claim 4 , wherein the active ingredient is for treatment of disease, and the composition is a pharmaceutical composition.

6. A mitochondria targeting delivery system for an active ingredient,

wherein the delivery system comprises the conjugate according to claim 1 , and

wherein the carrier peptide is a peptide that moves into a mitochondria locally and delivers the active ingredient to the mitochondria.

7. A composition for modulating mitochondria activity,

wherein the composition comprises the conjugate according to claim 1 ,

wherein the carrier peptide is a peptide that moves into a mitochondria locally and delivers the active ingredient to the mitochondria.

8. The conjugate according to claim 2 , wherein the protein is a cytokine, antibody, fragment of antibody, therapeutic enzyme, soluble receptor, or ligand.

9. The conjugate according to claim 2 , wherein the protein is an antibody or a fragment of antibody.

10. The conjugate according to claim 2 , wherein the protein is an enzyme or enzyme inhibitor.

11. The conjugate according to claim 2 , wherein the protein is a soluble receptor or ligand.

12. The conjugate according to claim 2 , wherein the protein is a vaccine.

13. The conjugate according to claim 2 , wherein the protein is a signal transfer protein.

14. The conjugate according to claim 2 , wherein the protein is a hormone or hormone analogue.

15. The conjugate according to claim 2 , wherein the linker is a Hynic linker.

16. The conjugate according to claim 1 , wherein more than one carrier peptide are connected to one active ingredient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036177/0728 →
Priority Claims (5)
KR 10-2012-0075444 · Jul 11, 2012 · national
KR 10-2012-0104173 · Sep 19, 2012 · national
KR 10-2012-0109207 · Sep 28, 2012 · national
KR 10-2013-0017046 · Feb 18, 2013 · national
KR 10-2013-0043635 · Apr 19, 2013 · national
Continuity (1)
Related Publication 20160151512A1 · Jun 2, 2016